Copyright © 2008 Liliane Michalik and Walter Wahli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. P. Wymann and R. Schneiter, “Lipid signalling in disease,” Nature Reviews Molecular Cell Biology, vol. 9, no. 2, pp. 162–176, 2008. View at Publisher · View at Google Scholar · View at PubMed
2. B. Desvergne, L. Michalik, and W. Wahli, “Transcriptional regulation of metabolism,” Physiological Reviews, vol. 86, no. 2, pp. 465–514, 2006. View at Publisher · View at Google Scholar · View at PubMed
3. R. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005. View at Publisher · View at Google Scholar
4. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
5. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal $\beta$-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar
6. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at PubMed
7. L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004. View at Publisher · View at Google Scholar · View at PubMed
8. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-$\alpha$, -$\beta$, and -$\gamma$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
9. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
10. H. Keller, C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli, “Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 6, pp. 2160–2164, 1993. View at Publisher · View at Google Scholar
11. S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992. View at Publisher · View at Google Scholar · View at PubMed
12. L. Michalik, J. Auwerx, J. P. Berger, et al., “International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at PubMed
13. G. Schmitz and J. Ecker, “The opposing effects of n-3 and n-6 fatty acids,” Progress in Lipid Research, vol. 47, no. 2, pp. 147–155, 2008. View at Publisher · View at Google Scholar · View at PubMed
14. P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPAR$\alpha$-leukotriene B4 pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996. View at Publisher · View at Google Scholar · View at PubMed
15. A. A. Spector and A. W. Norris, “Action of epoxyeicosatrienoic acids on cellular function,” American Journal of Physiology, vol. 292, no. 3, pp. C996–C1012, 2007. View at Publisher · View at Google Scholar · View at PubMed
16. J. Wray and D. Bishop-Bailey, “Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology,” Experimental Physiology, vol. 93, no. 1, pp. 148–154, 2008. View at Publisher · View at Google Scholar · View at PubMed
17. W. Jin, D. Marchadier, and D. J. Rader, “Lipases and HDL metabolism,” Trends in Endocrinology and Metabolism, vol. 13, no. 4, pp. 174–178, 2002. View at Publisher · View at Google Scholar
18. O. Ziouzenkova, S. Perrey, L. Asatryan, et al., “Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2730–2735, 2003. View at Publisher · View at Google Scholar · View at PubMed
19. W. Ahmed, O. Ziouzenkova, J. Brown, et al., “PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?,” Journal of Internal Medicine, vol. 262, no. 2, pp. 184–198, 2007. View at Publisher · View at Google Scholar · View at PubMed
20. W. Ahmed, G. Orasanu, V. Nehra, et al., “High-density lipoprotein hydrolysis by endothelial lipase activates PPAR$\alpha$: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion,” Circulation Research, vol. 98, no. 4, pp. 490–498, 2006. View at Publisher · View at Google Scholar · View at PubMed
21. A. Chawla, C.-H. Lee, Y. Barak, et al., “PPAR$\delta$ is a very low-density lipoprotein sensor in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1268–1273, 2003. View at Publisher · View at Google Scholar · View at PubMed
22. R. Zimmermann, J. G. Strauss, G. Haemmerle, et al., “Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase,” Science, vol. 306, no. 5700, pp. 1383–1386, 2004. View at Publisher · View at Google Scholar · View at PubMed
23. C. M. Jenkins, D. J. Mancuso, W. Yan, H. F. Sims, B. Gibson, and R. W. Gross, “Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 48968–48975, 2004. View at Publisher · View at Google Scholar · View at PubMed
24. J. A. Villena, S. Roy, E. Sarkadi-Nagy, K.-H. Kim, and S. S. Hei, “Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis,” The Journal of Biological Chemistry, vol. 279, no. 45, pp. 47066–47075, 2004. View at Publisher · View at Google Scholar · View at PubMed
25. A. Chmurzyńska, “The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism,” Journal of Applied Genetics, vol. 47, no. 1, pp. 39–48, 2006.
26. N. H. Haunerland and F. Spener, “Fatty acid-binding proteins–insights from genetic manipulations,” Progress in Lipid Research, vol. 43, no. 4, pp. 328–349, 2004. View at Publisher · View at Google Scholar · View at PubMed
27. N.-S. Tan, N. S. Shaw, N. Vinckenbosch, et al., “Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription,” Molecular and Cellular Biology, vol. 22, no. 14, pp. 5114–5127, 2002. View at Publisher · View at Google Scholar
28. L. Michalik and W. Wahli, “Guiding ligands to nuclear receptors,” Cell, vol. 129, no. 4, pp. 649–651, 2007. View at Publisher · View at Google Scholar · View at PubMed
29. T. T. Schug, D. C. Berry, N. S. Shaw, S. N. Travis, and N. Noy, “Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors,” Cell, vol. 129, no. 4, pp. 723–733, 2007. View at Publisher · View at Google Scholar · View at PubMed
30. K. Fujishiro, Y. Fukui, O. Sato, K. Kawabe, K. Seto, and K. Motojima, “Analysis of tissue-specific and PPAR$\alpha$-dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method,” Molecular and Cellular Biochemistry, vol. 239, no. 1-2, pp. 165–172, 2002. View at Publisher · View at Google Scholar
31. H. Poirier, I. Niot, M.-C. Monnot, et al., “Differential involvement of peroxisome-proliferator-activated receptors $\alpha$ and $\delta$ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine,” Biochemical Journal, vol. 355, part 2, pp. 481–488, 2001. View at Publisher · View at Google Scholar
32. F. Schroeder, A. D. Petrescu, H. Huang, et al., “Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription,” Lipids, vol. 43, no. 1, pp. 1–17, 2008. View at Publisher · View at Google Scholar · View at PubMed
33. G. Dranoff, “Cytokines in cancer pathogenesis and cancer therapy,” Nature Reviews Cancer, vol. 4, no. 1, pp. 11–22, 2004. View at Publisher · View at Google Scholar · View at PubMed
34. W.-W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175–1183, 2007. View at Publisher · View at Google Scholar · View at PubMed
35. J. A. Van Ginderachter, K. Movahedi, J. Van den Bossche, and P. De Baetselier, “Macrophages, PPARs, and cancer,” PPAR Research, vol. 2008, Article ID 169414, 11 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
36. M. Karin, “The I$\kappa$B kinase—a bridge between inflammation and cancer,” Cell Research, vol. 18, no. 3, pp. 334–342, 2008. View at Publisher · View at Google Scholar · View at PubMed
37. P. Boffetta, W. Ye, G. Boman, and O. Nyrén, “Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden,” European Respiratory Journal, vol. 19, no. 1, pp. 127–133, 2002. View at Publisher · View at Google Scholar
38. A. J. Sasco, R. M. Merrill, I. Dari, et al., “A case-control study of lung cancer in Casablanca, Morocco,” Cancer Causes and Control, vol. 13, no. 7, pp. 609–616, 2002. View at Publisher · View at Google Scholar
39. J. R. Mann, M. G. Backlund, and R. N. DuBois, “Mechanisms of disease: inflammatory mediators and cancer prevention,” Nature Clinical Practice Oncology, vol. 2, no. 4, pp. 202–210, 2005. View at Publisher · View at Google Scholar · View at PubMed
40. C. M. Ulrich, J. Bigler, and J. D. Potter, “Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics,” Nature Reviews Cancer, vol. 6, no. 2, pp. 130–140, 2006. View at Publisher · View at Google Scholar · View at PubMed
41. M. Karin and F. R. Greten, “NF-$\kappa$B: linking inflammation and immunity to cancer development and progression,” Nature Reviews Immunology, vol. 5, no. 10, pp. 749–759, 2005. View at Publisher · View at Google Scholar · View at PubMed
42. W. E. Naugler and M. Karin, “NF-$\kappa$B and cancer—identifying targets and mechanisms,” Current Opinion in Genetics & Development, vol. 18, no. 1, pp. 19–26, 2008. View at Publisher · View at Google Scholar · View at PubMed
43. E. Flossmann and P. M. Rothwell, “Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies,” The Lancet, vol. 369, no. 9573, pp. 1603–1613, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. W. Wahli, “A gut feeling of the PXR, PPAR and NF-$\kappa$B connection,” Journal of Internal Medicine, vol. 263, no. 6, pp. 613–619, 2008. View at Publisher · View at Google Scholar · View at PubMed
45. K. Tachibana, D. Yamasaki, K. Ishimoto, and T. Doi, “The role of PPARs in cancer,” PPAR Research, vol. 2008, Article ID 102737, 15 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
46. X. Y. Yang, L. H. Wang, and W. L. Farrar, “A role for PPAR$\gamma$ in the regulation of cytokines in immune cells and cancer,” PPAR Research, vol. 2008, Article ID 961753, 12 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
47. L. Michalik and W. Wahli, “Involvement of PPAR nuclear receptors in tissue injury and wound repair,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006. View at Publisher · View at Google Scholar · View at PubMed
48. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPAR$\gamma$ as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology and Therapy, vol. 4, no. 7, pp. 687–693, 2005.
49. R. Müller, M. Kömhoff, J. M. Peters, and S. Müller-Brüsselbach, “A role for PPAR$\beta$/$\delta$ in tumor stroma and tumorigenesis,” PPAR Research, vol. 2008, Article ID 534294, 5 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
50. D. Panigrahy, A. Kaipainen, S. Huang, et al., “PPAR$\alpha$ agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 3, pp. 985–990, 2008. View at Publisher · View at Google Scholar · View at PubMed
51. A. Kaipainen, M. W. Kieran, S. Huang, et al., “PPAR$\alpha$ deficiency in inflammatory cells suppresses tumor growth,” PLoS ONE, vol. 2, no. 2, p. e260, 2007. View at Publisher · View at Google Scholar · View at PubMed
52. L. Michalik and W. Wahli, “Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 991–998, 2007. View at Publisher · View at Google Scholar · View at PubMed
53. M. Schmuth, Y. J. Jiang, S. Dubrac, P. M. Elias, and K. R. Feingold, “Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology,” Journal of Lipid Research, vol. 49, no. 3, pp. 499–509, 2008. View at Publisher · View at Google Scholar · View at PubMed
54. B. M. Hantash, L. Zhao, J. A. Knowles, and H. P. Lorenz, “Adult and fetal wound healing,” Frontiers in Bioscience, vol. 13, no. 1, pp. 51–61, 2008. View at Publisher · View at Google Scholar
55. L. Michalik, B. Desvergne, N. S. Tan, et al., “Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)$\alpha$ and PPAR$\beta$ mutant mice,” Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001. View at Publisher · View at Google Scholar · View at PubMed
56. L. Michalik, J. N. Feige, L. Gelman, et al., “Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing,” Molecular Endocrinology, vol. 19, no. 9, pp. 2335–2348, 2005. View at Publisher · View at Google Scholar · View at PubMed
57. N. S. Tan, L. Michalik, N. Noy, et al., “Critical roles of PPAR$\beta$/$\delta$ in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 24, pp. 3263–3277, 2001. View at Publisher · View at Google Scholar · View at PubMed
58. N. S. Tan, L. Michalik, N. Di-Poï, et al., “Essential role of Smad3 in the inhibition of inflammation-induced PPAR$\beta$/$\delta$ expression,” The EMBO Journal, vol. 23, no. 21, pp. 4211–4221, 2004. View at Publisher · View at Google Scholar · View at PubMed
59. N. Di-Poï, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, “Antiapoptotic role of PPAR$\beta$ in keratinocytes via transcriptional control of the Akt1 signaling pathway,” Molecular Cell, vol. 10, no. 4, pp. 721–733, 2002. View at Publisher · View at Google Scholar
60. N. S. Tan, G. Icre, A. Montagner, B. Bordier-ten Heggeler, W. Wahli, and L. Michalik, “The nuclear hormone receptor peroxisome proliferator-activated receptor $\beta$/$\delta$ potentiates cell chemotactism, polarization, and migration,” Molecular and Cellular Biology, vol. 27, no. 20, pp. 7161–7175, 2007. View at Publisher · View at Google Scholar · View at PubMed
61. G. S. Ashcroft, X. Yang, A. B. Glick, et al., “Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response,” Nature Cell Biology, vol. 1, no. 5, pp. 260–266, 1999. View at Publisher · View at Google Scholar · View at PubMed
62. N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Genetic- or transforming growth factor-$\beta$1-induced changes in epidermal peroxisome proliferator-activated receptor $\beta$/$\delta$ expression dictate wound repair kinetics,” The Journal of Biological Chemistry, vol. 280, no. 18, pp. 18163–18170, 2005. View at Publisher · View at Google Scholar · View at PubMed
63. D. Y. M. Leung and T. Bieber, “Atopic dermatitis,” The Lancet, vol. 361, no. 9352, pp. 151–160, 2003. View at Publisher · View at Google Scholar · View at PubMed
64. M. P. Schön and W.-H. Boehncke, “Psoriasis,” The New England Journal of Medicine, vol. 352, no. 18, pp. 1899–1912, 2005. View at Publisher · View at Google Scholar · View at PubMed
65. M. Westergaard, J. Henningsen, C. Johansen, et al., “Expression and localization of peroxisome proliferator-activated receptors and nuclear factor $\kappa$B in normal and lesional psoriatic skin,” Journal of Investigative Dermatology, vol. 121, no. 5, pp. 1104–1117, 2003. View at Publisher · View at Google Scholar · View at PubMed
66. M. Rivier, I. Safonova, P. Lebrun, C. E. M. Griffiths, G. Ailhaud, and S. Michel, “Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes,” Journal of Investigative Dermatology, vol. 111, no. 6, pp. 1116–1121, 1998. View at Publisher · View at Google Scholar · View at PubMed
67. L. G. Kömüves, K. Hanley, A.-M. Lefebvre, et al., “Stimulation of PPAR$\alpha$ promotes epidermal keratinocyte differentiation in vivo,” Journal of Investigative Dermatology, vol. 115, no. 3, pp. 353–360, 2000. View at Publisher · View at Google Scholar · View at PubMed
68. M. Y. Sheu, A. J. Fowler, J. Kao, et al., “Topical peroxisome proliferator activated receptor-$\alpha$ activators reduce inflammation in irritant and allergic contact dermatitis models,” Journal of Investigative Dermatology, vol. 118, no. 1, pp. 94–101, 2002. View at Publisher · View at Google Scholar · View at PubMed
69. D. Staumont-Sallé, G. Abboud, C. Brénuchon, et al., “Peroxisome proliferator-activated receptor $\alpha$ regulates skin inflammation and humoral response in atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 121, no. 4, pp. 962–968.e6, 2008. View at Publisher · View at Google Scholar · View at PubMed
70. J. Lo Verme, J. Fu, G. Astarita, et al., “The nuclear receptor peroxisome proliferator-activated receptor-$\alpha$ mediates the anti-inflammatory actions of palmitoylethanolamide,” Molecular Pharmacology, vol. 67, no. 1, pp. 15–19, 2005. View at Publisher · View at Google Scholar · View at PubMed
71. C. N. Ellis, J. Varani, G. J. Fisher, et al., “Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-$\gamma$ inhibit keratinocyte proliferation,” Archives of Dermatology, vol. 136, no. 5, pp. 609–616, 2000. View at Publisher · View at Google Scholar
72. M. Demerjian, M.-Q. Man, E.-H. Choi, et al., “Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-$\gamma$, normalizes epidermal homeostasis in a murine hyperproliferative disease model,” Experimental Dermatology, vol. 15, no. 3, pp. 154–160, 2006. View at Publisher · View at Google Scholar · View at PubMed
73. S. Kuenzli and J.-H. Saurat, “Effect of topical PPAR$\beta$/$\delta$ and PPAR$\gamma$ agonists on plaque psoriasis: a pilot study,” Dermatology, vol. 206, no. 3, pp. 252–256, 2003. View at Publisher · View at Google Scholar · View at PubMed
74. S. Kuenzli and J.-H. Saurat, “Retinoids for the treatment of psoriasis: outlook for the future,” Current Opinion in Investigational Drugs, vol. 2, no. 5, pp. 625–630, 2001.
75. J. Varani, N. Bhagavathula, C. N. Ellis, and H. A. Pershadsingh, “Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease,” Expert Opinion on Investigational Drugs, vol. 15, no. 11, pp. 1453–1468, 2006. View at Publisher · View at Google Scholar · View at PubMed
76. A. S. Boyd, “Thiazolidinediones in dermatology,” International Journal of Dermatology, vol. 46, no. 6, pp. 557–563, 2007. View at Publisher · View at Google Scholar · View at PubMed
77. H. Y. Kang, J. Y. Lee, J. S. Lee, and Y. M. Choi, “Peroxisome proliferator-activated receptors-$\gamma$ activator, ciglitazone, inhibits human melanocyte growth through induction of apoptosis,” Archives of Dermatological Research, vol. 297, no. 10, pp. 472–476, 2006. View at Publisher · View at Google Scholar · View at PubMed
78. H. Y. Kang, E. Chung, M. Lee, Y. Cho, and W. H. Kang, “Expression and function of peroxisome proliferator-activated receptors in human melanocytes,” British Journal of Dermatology, vol. 150, no. 3, pp. 462–468, 2004. View at Publisher · View at Google Scholar · View at PubMed
79. R. Mössner, U. Schulz, U. Krüger, et al., “Agonists of peroxisome proliferator-activated receptor $\gamma$ inhibit cell growth in malignant melanoma,” Journal of Investigative Dermatology, vol. 119, no. 3, pp. 576–582, 2002. View at Publisher · View at Google Scholar · View at PubMed
80. M. Grabacka, W. Placha, P. M. Plonka, and S. Pajak, “Inhibition of melanoma metastases by fenofibrate,” Archives of Dermatological Research, vol. 296, no. 2, pp. 54–58, 2004. View at Publisher · View at Google Scholar · View at PubMed
81. A. Reichle, K. Bross, T. Vogt, et al., “Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma,” Cancer, vol. 101, no. 10, pp. 2247–2256, 2004. View at Publisher · View at Google Scholar · View at PubMed
82. R. Mössner, P. Meyer, F. Jankowski, et al., “Variations in the peroxisome proliferator-activated receptor-$\gamma$ gene and melanoma risk,” Cancer Letters, vol. 246, no. 1-2, pp. 218–223, 2007. View at Publisher · View at Google Scholar · View at PubMed
83. E. C. Jaeckel, S. Raja, J. Tan, et al., “Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor $\delta$ with head and neck squamous cell carcinoma,” Archives of Otolaryngology—Head & Neck Surgery, vol. 127, no. 10, pp. 1253–1259, 2001.
84. D. J. Kim, T. E. Akiyama, F. S. Harman, et al., “Peroxisome proliferator-activated receptor $\beta$ ($\delta$)-dependent regulation of ubiquatin C expression contributes to attenuation of skin carcinogenesis,” The Journal of Biological Chemistry, vol. 279, no. 22, pp. 23719–23727, 2004. View at Publisher · View at Google Scholar · View at PubMed
85. D. J. Kim, I. A. Murray, A. M. Burns, F. J. Gonzalez, G. H. Perdew, and J. M. Peters, “Peroxisome proliferator-activated receptor-$\beta$/$\delta$ inhibits epidermal cell proliferation by down-regulation of kinase activity,” The Journal of Biological Chemistry, vol. 280, no. 10, pp. 9519–9527, 2005. View at Publisher · View at Google Scholar · View at PubMed
86. A. K. Indra, E. Castaneda, M. C. Antal, et al., “Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor $\alpha$ in epidermal keratinocytes,” Journal of Investigative Dermatology, vol. 127, no. 5, pp. 1250–1260, 2007. View at Publisher · View at Google Scholar · View at PubMed
87. P. Thuillier, G. J. Anchiraico, K. P. Nickel, et al., “Activators of peroxisome proliferator-activated receptor-$\alpha$ partially inhibit mouse skin tumor promotion,” Molecular Carcinogenesis, vol. 29, no. 3, pp. 134–142, 2000. View at Publisher · View at Google Scholar
88. S. Kippenberger, S. M. Loitsch, M. Grundmann-Kollmann, et al., “Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation,” Journal of Investigative Dermatology, vol. 117, no. 6, pp. 1430–1436, 2001. View at Publisher · View at Google Scholar · View at PubMed
89. G. He, S. Muga, P. Thuillier, R. A. Lubet, and S. M. Fischer, “The effect of PPAR$\gamma$ ligands on UV- or chemically-induced carcinogenesis in mouse skin,” Molecular Carcinogenesis, vol. 43, no. 4, pp. 198–206, 2005. View at Publisher · View at Google Scholar · View at PubMed
90. C. J. Nicol, M. Yoon, J. M. Ward, et al., “PPAR$\gamma$ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis,” Carcinogenesis, vol. 25, no. 9, pp. 1747–1755, 2004. View at Publisher · View at Google Scholar · View at PubMed
91. Q. Zhang, M. D. Southall, S. M. Mezsick, et al., “Epidermal peroxisome proliferator-activated receptor $\gamma$ as a target for ultraviolet B radiation,” The Journal of Biological Chemistry, vol. 280, no. 1, pp. 73–79, 2005. View at Publisher · View at Google Scholar · View at PubMed
92. R. J. Xavier and D. K. Podolsky, “Unravelling the pathogenesis of inflammatory bowel disease,” Nature, vol. 448, no. 7152, pp. 427–434, 2007. View at Publisher · View at Google Scholar · View at PubMed
93. J. W. Lee, P. J. Bajwa, M. J. Carson, et al., “Fenofibrate represses interleukin-17 and interferon-$\gamma$ expression and improves colitis in interleukin-10-deficient mice,” Gastroenterology, vol. 133, no. 1, pp. 108–123, 2007. View at Publisher · View at Google Scholar · View at PubMed
94. T. Tanaka, H. Kohno, S.-I. Yoshitani, et al., “Ligands for peroxisome proliferator-activated receptors $\alpha$ and $\gamma$ inhibit chemically induced colitis and formation of aberrant crypt foci in rats,” Cancer Research, vol. 61, no. 6, pp. 2424–2428, 2001.
95. P. Desreumaux, L. Dubuquoy, S. Nutten, et al., “Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$) heterodimer: a basis for new therapeutic strategies,” Journal of Experimental Medicine, vol. 193, no. 7, pp. 827–838, 2001. View at Publisher · View at Google Scholar
96. C. G. Su, X. Wen, S. T. Bailey, et al., “A novel therapy for colitis utilizing PPAR-$\gamma$ ligands to inhibit the epithelial inflammatory response,” Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999. View at Publisher · View at Google Scholar · View at PubMed
97. J. D. Ramakers, M. I. Verstege, G. Thuijls, A. A. Te Velde, R. P. Mensink, and J. Plat, “The PPAR$\gamma$ agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis,” Journal of Clinical Immunology, vol. 27, no. 3, pp. 275–283, 2007. View at Publisher · View at Google Scholar · View at PubMed
98. K. Katayama, K. Wada, A. Nakajima, et al., “A novel PPAR$\gamma$ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model,” Gastroenterology, vol. 124, no. 5, pp. 1315–1324, 2003. View at Publisher · View at Google Scholar
99. L. J. Saubermann, A. Nakajima, K. Wada, et al., “Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis,” Inflammatory Bowel Diseases, vol. 8, no. 5, pp. 330–339, 2002. View at Publisher · View at Google Scholar
100. M. Sánchez-Hidalgo, A. R. Martín, I. Villegas, and C. Alarcón de la Lastra, “Rosiglitazone, a PPAR$\gamma$ ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats,” European Journal of Pharmacology, vol. 562, no. 3, pp. 247–258, 2007. View at Publisher · View at Google Scholar · View at PubMed
101. Á. Ponferrada, J. R. Caso, L. Alou, et al., “The role of PPAR$\gamma$ on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction,” Gastroenterology, vol. 132, no. 5, pp. 1791–1803, 2007. View at Publisher · View at Google Scholar · View at PubMed
102. A. Nakajima, K. Wada, H. Miki, et al., “Endogenous PPAR$\gamma$ mediates anti-inflammatory activity in murine ischemia-reperfusion injury,” Gastroenterology, vol. 120, no. 2, pp. 460–469, 2001. View at Publisher · View at Google Scholar
103. S. Cuzzocrea, B. Pisano, L. Dugo, et al., “Rosiglitazone and 15-deoxy-${\mathrm{\Delta }}^{12,14}$-prostaglandin ${\text{J}}_2$, ligands of the peroxisome proliferator-activated receptor-$\gamma$ (PPAR-$\gamma$), reduce ischaemia/reperfusion injury of the gut,” British Journal of Pharmacology, vol. 140, no. 2, pp. 366–376, 2003. View at Publisher · View at Google Scholar · View at PubMed
104. Y. M. Shah, K. Morimura, and F. J. Gonzalez, “Expression of peroxisome proliferator-activated receptor-$\gamma$ in macrophage suppresses experimentally induced colitis,” American Journal of Physiology, vol. 292, no. 2, pp. G657–G666, 2007. View at Publisher · View at Google Scholar · View at PubMed
105. R. Hontecillas and J. Bassaganya-Riera, “Peroxisome proliferator-activated receptor $\gamma$ is required for regulatory ${\text{CD4}}^{+}$ T cell-mediated protection against colitis,” The Journal of Immunology, vol. 178, no. 5, pp. 2940–2949, 2007.
106. Y. Naito, T. Takagi, K. Uchiyama, et al., “Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-$\gamma$ ligand, pioglitazone, in rats,” Redox Report, vol. 7, no. 5, pp. 294–299, 2002. View at Publisher · View at Google Scholar
107. X. Han, N. Benight, B. Osuntokun, K. Loesch, S. J. Frank, and L. A. Denson, “Tumour necrosis factor $\alpha$ blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis,” Gut, vol. 56, no. 1, pp. 73–81, 2007. View at Publisher · View at Google Scholar · View at PubMed
108. J. D. Lewis, G. R. Lichtenstein, R. B. Stein, et al., “An open-label trial of the PPAR$\gamma$ ligand rosiglitazone for active ulcerative colitis,” The American Journal of Gastroenterology, vol. 96, no. 12, pp. 3323–3328, 2001. View at Publisher · View at Google Scholar
109. C. Rousseaux, B. Lefebvre, L. Dubuquoy, et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-$\gamma$,” Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005. View at Publisher · View at Google Scholar · View at PubMed
110. P. C. Konturek, T. Brzozowski, J. Kania, et al., “Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat,” Scandinavian Journal of Gastroenterology, vol. 38, no. 5, pp. 468–476, 2003. View at Publisher · View at Google Scholar
111. P. C. Konturek, T. Brzozowski, J. Kania, et al., “Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat,” European Journal of Pharmacology, vol. 472, no. 3, pp. 213–220, 2003. View at Publisher · View at Google Scholar
112. B. L. Slomiany and A. Slomiany, “Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor $\gamma$ activation,” IUBMB Life, vol. 53, no. 6, pp. 303–308, 2002. View at Publisher · View at Google Scholar · View at PubMed
113. I. Villegas, A. R. Martín, W. Toma, and C. Alarcón de La Lastra, “Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation,” European Journal of Pharmacology, vol. 505, no. 1–3, pp. 195–203, 2004. View at Publisher · View at Google Scholar · View at PubMed
114. K. Wada, A. Nakajima, H. Takahashi, et al., “Protective effect of endogenous PPAR$\gamma$ against acute gastric mucosal lesions associated with ischemia-reperfusion,” American Journal of Physiology, vol. 287, no. 2, pp. G452–G458, 2004. View at Publisher · View at Google Scholar · View at PubMed
115. H. Ichikawa, Y. Naito, T. Takagi, N. Tomatsuri, N. Yoshida, and T. Yoshikawa, “A specific peroxisome proliferator-induced receptor-$\gamma$ (PPAR-$\gamma$) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats,” Redox Report, vol. 7, no. 5, pp. 343–346, 2002. View at Publisher · View at Google Scholar
116. K. Shimizu, K. Shiratori, N. Hayashi, T. Fujiwara, and H. Horikoshi, “Effect of troglitazone on exocrine pancreas in rats with streptozotocin-induced diabetes mellitus,” Pancreas, vol. 21, no. 4, pp. 421–426, 2000. View at Publisher · View at Google Scholar
117. K. Shimizu, K. Shiratori, N. Hayashi, M. Kobayashi, T. Fujiwara, and H. Horikoshi, “Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis,” Pancreas, vol. 24, no. 2, pp. 184–190, 2002. View at Publisher · View at Google Scholar
118. K. Shimizu, M. Kobayashi, J. Tahara, and K. Shiratori, “Cytokines and peroxisome proliferator-activated receptor $\gamma$ ligand regulate phagocytosis by pancreatic stellate cells,” Gastroenterology, vol. 128, no. 7, pp. 2105–2118, 2005. View at Publisher · View at Google Scholar
119. S. Cuzzocrea, B. Pisano, L. Dugo, et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein,” Intensive Care Medicine, vol. 30, no. 5, pp. 951–956, 2004. View at Publisher · View at Google Scholar · View at PubMed
120. K. Hashimoto, R. T. Ethridge, H. Saito, S. Rajaraman, and B. M. Evers, “The PPAR$\gamma$ ligand, 15d-PGJ2, attenuates the severity of cerulein-induced acute pancreatitis,” Pancreas, vol. 27, no. 1, pp. 58–66, 2003. View at Publisher · View at Google Scholar
121. D. J. van Westerloo, S. Florquin, A. M. de Boer, et al., “Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice,” The American Journal of Pathology, vol. 166, no. 3, pp. 721–728, 2005.
122. E. Mazzon and S. Cuzzocrea, “Absence of functional peroxisome proliferator-activated receptor-$\alpha$ enhanced ileum permeability during experimental colitis,” Shock, vol. 28, no. 2, pp. 192–201, 2007. View at Publisher · View at Google Scholar · View at PubMed
123. H. E. Hollingshead, K. Morimura, M. Adachi, et al., “PPAR$\beta$/$\delta$ protects against experimental colitis through a ligand-independent mechanism,” Digestive Diseases and Sciences, vol. 52, no. 11, pp. 2912–2919, 2007. View at Publisher · View at Google Scholar · View at PubMed
124. J. P. Iredale, “Cirrhosis: new research provides a basis for rational and targeted treatments,” British Medical Journal, vol. 327, no. 7407, pp. 143–147, 2003. View at Publisher · View at Google Scholar · View at PubMed
125. K. Hellemans, L. Michalik, A. Dittie, et al., “Peroxisome proliferator-activated receptor-$\beta$ signaling contributes to enhanced proliferation of hepatic stellate cells,” Gastroenterology, vol. 124, no. 1, pp. 184–201, 2003. View at Publisher · View at Google Scholar · View at PubMed
126. T. Okaya and A. B. Lentsch, “Peroxisome proliferator-activated receptor-$\alpha$ regulates postischemic liver injury,” American Journal of Physiology, vol. 286, no. 4, pp. G606–G612, 2004.
127. T. Toyama, H. Nakamura, Y. Harano, et al., “PPAR$\alpha$ ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats,” Biochemical and Biophysical Research Communications, vol. 324, no. 2, pp. 697–704, 2004. View at Publisher · View at Google Scholar · View at PubMed
128. A. Masamune, K. Kikuta, M. Satoh, Y. Sakai, A. Satoh, and T. Shimosegawa, “Ligands of peroxisome proliferator-activated receptor-$\gamma$ block activation of pancreatic stellate cells,” The Journal of Biological Chemistry, vol. 277, no. 1, pp. 141–147, 2002. View at Publisher · View at Google Scholar · View at PubMed
129. C. Zhao, W. Chen, L. Yang, L. Chen, S. A. Stimpson, and A. M. Diehl, “PPAR$\gamma$ agonists prevent TGF$\beta$1/Smad3-signaling in human hepatic stellate cells,” Biochemical and Biophysical Research Communications, vol. 350, no. 2, pp. 385–391, 2006. View at Publisher · View at Google Scholar · View at PubMed
130. H. She, S. Xiong, S. Hazra, and H. Tsukamoto, “Adipogenic transcriptional regulation of hepatic stellate cells,” The Journal of Biological Chemistry, vol. 280, no. 6, pp. 4959–4967, 2005. View at Publisher · View at Google Scholar · View at PubMed
131. S. Yavrom, L. Chen, S. Xiong, J. Wang, R. A. Rippe, and H. Tsukamoto, “Peroxisome proliferator-activated receptor $\gamma$ suppresses proximal $\alpha$1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells,” The Journal of Biological Chemistry, vol. 280, no. 49, pp. 40650–40659, 2005. View at Publisher · View at Google Scholar · View at PubMed
132. S. Hazra, S. Xiong, J. Wang, R. A. Rippe, V. K. K. Chatterjee, and H. Tsukamoto, “Peroxisome proliferator-activated receptor $\gamma$ induces a phenotypic switch from activated to quiescent hepatic stellate cells,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11392–11401, 2004. View at Publisher · View at Google Scholar · View at PubMed
133. A. Galli, D. W. Crabb, E. Ceni, et al., “Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro,” Gastroenterology, vol. 122, no. 7, pp. 1924–1940, 2002. View at Publisher · View at Google Scholar
134. F. Marra, E. Efsen, R. G. Romanelli, et al., “Ligands of peroxisome proliferator-activated receptor $\gamma$ modulate profibrogenic and proinflammatory actions in hepatic stellate cells,” Gastroenterology, vol. 119, no. 2, pp. 466–478, 2000. View at Publisher · View at Google Scholar
135. T. Miyahara, L. Schrum, R. Rippe, et al., “Peroxisome proliferator-activated receptors and hepatic stellate cell activation,” The Journal of Biological Chemistry, vol. 275, no. 46, pp. 35715–35722, 2000. View at Publisher · View at Google Scholar · View at PubMed
136. J. Xu, Y. Fu, and A. Chen, “Activation of peroxisome proliferator-activated receptor-$\gamma$ contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth,” American Journal of Physiology, vol. 285, no. 1, pp. G20–G30, 2003.
137. E. Ceni, D. W. Crabb, M. Foschi, et al., “Acetaldehyde inhibits PPAR$\gamma$ via ${\text{H}}_2{\text{O}}_2$-mediated c-Abl activation in human hepatic stellate cells,” Gastroenterology, vol. 131, no. 4, pp. 1235–1252, 2006. View at Publisher · View at Google Scholar · View at PubMed
138. D. Wang and R. N. DuBois, “Peroxisome proliferator-activated receptors and progression of colorectal cancer,” PPAR Research, vol. 2008, Article ID 931074, 7 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
139. P. Shaw and A. R. Clarke, “Murine models of intestinal cancer: recent advances,” DNA Repair, vol. 6, no. 10, pp. 1403–1412, 2007. View at Publisher · View at Google Scholar · View at PubMed
140. P. Desreumaux and S. Ghosh, “Review article: mode of action and delivery of 5-aminosalicylic acid—new evidence,” Alimentary Pharmacology & Therapeutics, vol. 24, pp. 2–9, 2006. View at Publisher · View at Google Scholar · View at PubMed
141. I. Ikeda, A. Tomimoto, K. Wada, et al., “5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model,” Clinical Cancer Research, vol. 13, no. 21, pp. 6527–6531, 2007. View at Publisher · View at Google Scholar · View at PubMed
142. H. Kohno, R. Suzuki, S. Sugie, and T. Tanaka, “Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands,” BMC Cancer, vol. 5, article 46, pp. 1–12, 2005. View at Publisher · View at Google Scholar · View at PubMed
143. E. Osawa, A. Nakajima, K. Wada, et al., “Peroxisome proliferator-activated receptor $\gamma$ ligands suppress colon carcinogenesis induced by azoxymethane in mice,” Gastroenterology, vol. 124, no. 2, pp. 361–367, 2003. View at Publisher · View at Google Scholar · View at PubMed
144. P. C. Konturek, S. J. Konturek, and T. Brzozowski, “Gastric cancer and Helicobacter pylori infection,” Journal of Physiology and Pharmacology, vol. 57, pp. 51–65, 2006.
145. P. C. Konturek, J. Kania, V. Kukharsky, et al., “Implication of peroxisome proliferator-activated receptor $\gamma$ and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection,” Journal of Pharmacological Sciences, vol. 96, no. 2, pp. 134–143, 2004. View at Publisher · View at Google Scholar
146. P. C. Konturek, S. J. Konturek, W. Bielanski, et al., “Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPAR$\gamma$ and apoptosis-related proteins in gastric cancer patients,” Digestive Diseases and Sciences, vol. 48, no. 10, pp. 2005–2017, 2003. View at Publisher · View at Google Scholar
147. T. Tahara, T. Arisawa, T. Shibata, F. Yuwang, I. Hirata, and H. Nakano, “Peroxisome proliferator-activated receptor gamma Plo12Ala polymorphism influences the susceptibility of a Japanese population to gastric cancer,” Scandinavian Journal of Gastroenterology, pp. 1–7, 2007. View at Publisher · View at Google Scholar · View at PubMed
148. G. Eibl, “The role of PPAR-$\gamma$ and its interaction with COX-2 in pancreatic cancer,” PPAR Research, vol. 2008, Article ID 326915, 6 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
149. Y. Takeuchi, M. Takahashi, K. Sakano, et al., “Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor $\gamma$,” Carcinogenesis, vol. 28, no. 8, pp. 1692–1696, 2007. View at Publisher · View at Google Scholar · View at PubMed
150. G. Kristiansen, J. Jacob, A.-C. Buckendahl, et al., “Peroxisome proliferator-activated receptor $\gamma$ is highly expressed in pancreatic cancer and is associated with shorter overall survival times,” Clinical Cancer Research, vol. 12, no. 21, pp. 6444–6451, 2006. View at Publisher · View at Google Scholar · View at PubMed
151. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPAR$\gamma$ in human and mouse physiology,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar · View at PubMed
152. J. H. Chung, A. Y. Seo, S. W. Chung, et al., “Molecular mechanism of PPAR in the regulation of age-related inflammation,” Ageing Research Reviews, vol. 7, no. 2, pp. 126–136, 2008. View at Publisher · View at Google Scholar · View at PubMed
153. M. M. Masternak and A. Bartke, “PPARs in calorie restricted and genetically long-lived mice,” PPAR Research, vol. 2007, Article ID 28436, 7 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
154. M. E. Poynter and R. A. Daynes, “Peroxisome proliferator-activated receptor $\alpha$ activation modulates cellular redox status, represses nuclear factor-$\kappa$B signaling, and reduces inflammatory cytokine production in aging,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32833–32841, 1998. View at Publisher · View at Google Scholar
155. M. E. Poynter and R. A. Daynes, “Age-associated alterations in splenic iNOS regulation: influence of constitutively expressed IFN-$\gamma$ and correction following supplementation with PPAR$\alpha$ activators or vitamin E,” Cellular Immunology, vol. 195, no. 2, pp. 127–136, 1999. View at Publisher · View at Google Scholar · View at PubMed
156. B. Sung, S. Park, B. P. Yu, and H. Y. Chung, “Amelioration of age-related inflammation and oxidative stress by PPAR$\gamma$ activator: suppression of NF-$\kappa$B by 2,4-thiazolidinedione,” Experimental Gerontology, vol. 41, no. 6, pp. 590–599, 2006. View at Publisher · View at Google Scholar · View at PubMed
157. A. Jacob, R. Wu, M. Zhou, and P. Wang, “Mechanism of the anti-inflammatory effect of curcumin: PPAR-$\gamma$ activation,” PPAR Research, vol. 2007, Article ID 89369, 5 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
158. I. D'Errico and A. Moschetta, “Nuclear receptors, intestinal architecture and colon cancer: an intriguing link,” Cellular and Molecular Life Sciences, vol. 65, no. 10, pp. 1523–1543, 2008. View at Publisher · View at Google Scholar · View at PubMed
159. G. Gasparini, R. Longo, R. Sarmiento, and A. Morabito, “Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?,” Lancet Oncology, vol. 4, no. 10, pp. 605–615, 2003. View at Publisher · View at Google Scholar
160. M. Oshima, J. E. Dinchuk, S. L. Kargman, et al., “Suppression of intestinal polyposis in $AP{C}^{\mathrm{\Delta }716}$ knockout mice by inhibition of cyclooxygenase 2 (COX-2),” Cell, vol. 87, no. 5, pp. 803–809, 1996. View at Publisher · View at Google Scholar
161. P. Singh and A. Mittal, “Current status of COX-2 inhibitors,” Mini-Reviews in Medicinal Chemistry, vol. 8, no. 1, pp. 73–90, 2008. View at Publisher · View at Google Scholar
162. R. N. Reddy, R. Mutyala, P. Aparoy, P. Reddanna, and M. R. Reddy, “Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs,” Current Pharmaceutical Design, vol. 13, no. 34, pp. 3505–3517, 2007. View at Publisher · View at Google Scholar
163. R. Grau, C. Punzón, M. Fresno, and M. A. Iñiguez, “Peroxisome-proliferator-activated receptor $\alpha$ agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1,” Biochemical Journal, vol. 395, no. 1, pp. 81–88, 2006. View at Publisher · View at Google Scholar · View at PubMed
164. K. Yamazaki, M. Shimizu, M. Okuno, et al., “Synergistic effects of RXR$\alpha$ and PPAR$\gamma$ ligands to inhibit growth in human colon cancer cells—phosphorylated RXR$\alpha$ is a critical target for colon cancer management,” Gut, vol. 56, no. 11, pp. 1557–1563, 2007. View at Publisher · View at Google Scholar · View at PubMed
165. T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPAR$\delta$ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999. View at Publisher · View at Google Scholar
166. J. Shao, H. Sheng, and R. N. DuBois, “Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells,” Cancer Research, vol. 62, no. 11, pp. 3282–3288, 2002.
167. R. A. Gupta, J. Tan, W. F. Krause, et al., “Prostacyclin-mediated activation of peroxisome proliferator-activated receptor $\delta$ in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13275–13280, 2000. View at Publisher · View at Google Scholar · View at PubMed
168. D. Wang, H. Wang, Q. Shi, et al., “Prostaglandin ${\text{E}}_2$ promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor $\delta$,” Cancer Cell, vol. 6, no. 3, pp. 285–295, 2004. View at Publisher · View at Google Scholar · View at PubMed
169. L. Xu, C. Han, and T. Wu, “A novel positive feedback loop between peroxisome proliferator-activated receptor-$\delta$ and prostaglandin ${\text{E}}_2$ signaling pathways for human cholangiocarcinoma cell growth,” The Journal of Biological Chemistry, vol. 281, no. 45, pp. 33982–33996, 2006. View at Publisher · View at Google Scholar · View at PubMed
170. N. Di-Poï, Y. N. Chuan, S. T. Nguan, et al., “Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor $\beta$/$\delta$ during hair follicle development,” Molecular and Cellular Biology, vol. 25, no. 5, pp. 1696–1712, 2005. View at Publisher · View at Google Scholar · View at PubMed
171. G. G. Chen, J. F. Lee, S. H. Wang, U. P. F. Chan, P. C. Ip, and W. Y. Lau, “Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and Nf-$\kappa$B in human colon cancer,” Life Sciences, vol. 70, no. 22, pp. 2631–2646, 2002. View at Publisher · View at Google Scholar
172. F. T. Wunderlich, T. Luedde, S. Singer, et al., “Hepatic NF-$\kappa$B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, pp. 1297–1302, 2008. View at Publisher · View at Google Scholar · View at PubMed
173. W. E. Hardman, “(n-3) fatty acids and cancer therapy,” Journal of Nutrition, vol. 134, pp. 3427S–3430S, 2004.
174. H. Ruan, H. J. Pownall, and H. F. Lodish, “Troglitazone antagonizes tumor necrosis factor-$\alpha$-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-$\kappa$B,” The Journal of Biological Chemistry, vol. 278, no. 30, pp. 28181–28192, 2003. View at Publisher · View at Google Scholar · View at PubMed
175. A. S. Dhillon, S. Hagan, O. Rath, and W. Kolch, “MAP kinase signalling pathways in cancer,” Oncogene, vol. 26, no. 22, pp. 3279–3290, 2007. View at Publisher · View at Google Scholar · View at PubMed
176. K. A. Burns and J. P. Vanden Heuvel, “Modulation of PPAR activity via phosphorylation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 952–960, 2007. View at Publisher · View at Google Scholar · View at PubMed
177. D. C. Jones, X. Ding, T. Y. Zhang, and R. A. Daynes, “Peroxisome proliferator-activated receptor $\alpha$ negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation,” The Journal of Immunology, vol. 171, no. 1, pp. 196–203, 2003.
178. L. Tencer, E. Burgermeister, M. P. Ebert, and M. Liscovitch, “Rosiglitazone induces caveolin-1 by PPAR$\gamma$-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance,” Anticancer Research, vol. 28, no. 2A, pp. 895–906, 2008.
179. L. Chen, B. M. Necela, W. Su, et al., “Peroxisome proliferator-activated receptor $\gamma$ promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2,” The Journal of Biological Chemistry, vol. 281, no. 34, pp. 24575–24587, 2006. View at Publisher · View at Google Scholar · View at PubMed
180. M. Li, T. W. Lee, and A. P. C. Yim, “Apoptosis induced by troglitazone is both peroxisome proliterator-activated receptor-$\gamma$- and ERK-dependent in human non-small lung cancer cells,” Journal of Cellular Physiology, vol. 209, no. 2, pp. 428–438, 2006. View at Publisher · View at Google Scholar · View at PubMed
181. V. G. Keshamouni, R. C. Reddy, D. A. Arenberg, et al., “Peroxisome proliferator-activated receptor-$\gamma$ activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004. View at Publisher · View at Google Scholar · View at PubMed
182. R. A. Winn, M. Van Scoyk, M. Hammond, et al., “Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor $\gamma$,” The Journal of Biological Chemistry, vol. 281, no. 37, pp. 26943–26950, 2006. View at Publisher · View at Google Scholar · View at PubMed
183. C.-H. Woo, M. P. Massett, T. Shishido, et al., “ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor $\delta$ (PPAR$\delta$) stimulation,” The Journal of Biological Chemistry, vol. 281, no. 43, pp. 32164–32174, 2006. View at Publisher · View at Google Scholar · View at PubMed
184. E. Burgermeister and R. Seger, “PPAR$\gamma$ and MEK interactions in cancer,” PPAR Research, vol. 2008, Article ID 309469, 16 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
185. E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger, “Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor $\gamma$,” Molecular and Cellular Biology, vol. 27, no. 3, pp. 803–817, 2007. View at Publisher · View at Google Scholar · View at PubMed
186. I. Papadaki, E. Mylona, I. Giannopoulou, S. Markaki, A. Keramopoulos, and L. Nakopoulou, “PPAR$\gamma$ expression in breast cancer: clinical value and correlation with ER$\beta$,” Histopathology, vol. 46, no. 1, pp. 37–42, 2005. View at Publisher · View at Google Scholar · View at PubMed
187. P. Mukunyadzi, L. Ai, D. Portilla, E. L. Barnes, and C.-Y. Fan, “Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases,” Modern Pathology, vol. 16, no. 12, pp. 1218–1223, 2003. View at Publisher · View at Google Scholar · View at PubMed
188. T. Tamguney and D. Stokoe, “New insights into PTEN,” Journal of Cell Science, vol. 120, no. 23, pp. 4071–4079, 2007. View at Publisher · View at Google Scholar · View at PubMed
189. A. Carnero, C. Blanco-Aparicio, O. Renner, W. Link, and J. F. M. Leal, “The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications,” Current Cancer Drug Targets, vol. 8, no. 3, pp. 187–198, 2008. View at Publisher · View at Google Scholar
190. S. Wullschleger, R. Loewith, and M. N. Hall, “TOR signaling in growth and metabolism,” Cell, vol. 124, no. 3, pp. 471–484, 2006. View at Publisher · View at Google Scholar · View at PubMed
191. B.-H. Jiang and L.-Z. Liu, “Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment,” Drug Resistance Updates, vol. 11, no. 3, pp. 63–76, 2008. View at Publisher · View at Google Scholar · View at PubMed
192. S. Han, J. D. Ritzenthaler, Y. Zheng, and J. Roman, “PPAR$\beta$/$\delta$ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-$\kappa$B signals,” American Journal of Physiology, vol. 294, no. 6, pp. L1238–L1249, 2008.
193. S. Han, J. D. Ritzenthaler, B. Wingerd, and J. Roman, “Activation of peroxisome proliferator-activated receptor $\beta$/$\delta$ (PPAR$\beta$/$\delta$) increases the expression of prostaglandin ${\text{E}}_2$ receptor subtype EP4: the roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein $\beta$,” The Journal of Biological Chemistry, vol. 280, no. 39, pp. 33240–33249, 2005. View at Publisher · View at Google Scholar · View at PubMed
194. K. S. Lee, S. J. Park, P. H. Hwang, et al., “PPAR-gamma modulates allergic inflammation through up-regulation of PTEN,” FASEB Journal, vol. 19, no. 8, pp. 1033–1035, 2005. View at Publisher · View at Google Scholar · View at PubMed
195. S. Y. Lee, G. Y. Hur, K. H. Jung, et al., “PPAR-$\gamma$ agonist increase gefitinib's antitumor activity through PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2006. View at Publisher · View at Google Scholar · View at PubMed
196. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPAR$\gamma$-dependent and PPAR$\gamma$-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006. View at Publisher · View at Google Scholar · View at PubMed
197. G. He, Y. M. Sung, J. DiGiovanni, and S. M. Fischer, “Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity,” Cancer Research, vol. 66, no. 3, pp. 1873–1878, 2006. View at Publisher · View at Google Scholar · View at PubMed
198. W. Zhang, N. Wu, Z. Li, L. Wang, J. Jin, and X.-L. Zha, “PPAR$\gamma$ activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404,” Cancer Biology and Therapy, vol. 5, no. 8, pp. 1008–1014, 2006.
199. A. Aiello, G. Pandini, F. Frasca, et al., “Peroxisomal proliferator-activated receptor-$\gamma$ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006. View at Publisher · View at Google Scholar · View at PubMed
200. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1065–1081, 2007. View at Publisher · View at Google Scholar · View at PubMed